Literature DB >> 16932071

Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma.

Xiaohong Rose Yang1, Lori A Charette, Montserrat Garcia-Closas, Jolanta Lissowska, Edina Paal, Mary Sidawy, Stephen M Hewitt, David L Rimm, Mark E Sherman.   

Abstract

Construction of tissue microarrays (TMAs) to efficiently characterize large sets of noninvasive epithelial lesions in the breast by immunohistochemistry is an appealing investigative approach, but presents technical challenges. We report methodologic studies performed to optimize methods for building TMAs from noninvasive breast tissues collected in a large case-control study of breast cancer. Using a manual arraying technique with 2.0-mm diameter needles, we constructed TMAs from specimens obtained from 32 women with breast cancer containing the following targets: (1) 28 terminal duct lobular units (TDLUs); (2) 28 ductal carcinomas in situ, and (3) 23 invasive carcinomas. Using careful target selection, we achieved representation of approximately 80% of noninvasive targets with sustained preservation through section 30 of the TMAs. Immunohistochemical staining of TDLU targets demonstrated positive staining for estrogen receptor (ER) in 30.8% of tubules and for progesterone receptor (PR) in 50.0%. To establish an efficient method to evaluate staining results in TDLUs, we created a categorical scoring system to approximate the percentage of tubules containing positive stained cells (<10%, 10% to 50%, >or=50%), and compared the results with those obtained by tubule counting. Comparison between the two methods demonstrated exact agreement for 70.8% of ER and 79.2% of PR stains without two-category discrepancies. ER/PR expression levels in multiple (up to 4) noninvasive targets of the same tissue type (TDLU or DCIS) from a single block showed good correlation. These data suggest that it is feasible to produce TMAs of noninvasive breast structures, albeit with careful selection of targets, and that immunostains of such cores may permit efficient immunohistochemical characterization of peritumoral tissues. Additional exploration of this approach is needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932071     DOI: 10.1097/01.pdm.0000213453.45398.e0

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  9 in total

1.  Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Authors:  David L Rimm; Torsten O Nielsen; Scott D Jewell; Daniel C Rohrer; Gloria Broadwater; Frederic Waldman; Kisha A Mitchell; Baljit Singh; Gregory J Tsongalis; Wendy L Frankel; Anthony M Magliocco; Jonathan F Lara; Eric D Hsi; Ira J Bleiweiss; Sunil S Badve; Beiyun Chen; Peter M Ravdin; Richard L Schilsky; Ann Thor; Donald A Berry
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  A 'waterfall' transfer-based workflow for improved quality of tissue microarray construction and processing in breast cancer research.

Authors:  M Oberländer; H Alkemade; S Bünger; F Ernst; C Thorns; T Braunschweig; J K Habermann
Journal:  Pathol Oncol Res       Date:  2014-03-07       Impact factor: 3.201

3.  Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer.

Authors:  Xiaohong R Yang; Jonine D Figueroa; Stephen M Hewitt; Roni T Falk; Ruth M Pfeiffer; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Montserrat Garcia-Closas; Mark E Sherman
Journal:  Breast Cancer Res Treat       Date:  2012-12-28       Impact factor: 4.872

4.  Soy consumption and histopathologic markers in breast tissue using tissue microarrays.

Authors:  Gertraud Maskarinec; Eva Erber; Martijn Verheus; Brenda Y Hernandez; Jeffrey Killeen; Suzanne Cashin; J Mark Cline
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

5.  Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

Authors:  S E Clark; J Warwick; R Carpenter; R L Bowen; S W Duffy; J L Jones
Journal:  Br J Cancer       Date:  2010-12-07       Impact factor: 7.640

6.  Mammographic density and epithelial histopathologic markers.

Authors:  Martijn Verheus; Gertraud Maskarinec; Eva Erber; Jana S Steude; Jeffrey Killeen; Brenda Y Hernandez; J Mark Cline
Journal:  BMC Cancer       Date:  2009-06-13       Impact factor: 4.430

7.  Mammographic density and matrix metalloproteinases in breast tissue.

Authors:  Jana S Steude; Gertraud Maskarinec; Eva Erber; Martijn Verheus; Brenda Y Hernandez; Jeffrey Killeen; J Mark Cline
Journal:  Cancer Microenviron       Date:  2009-12-10

8.  COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.

Authors:  Swati Kulkarni; Deepa B Patil; Leslie K Diaz; Elizabeth L Wiley; Monica Morrow; Seema A Khan
Journal:  BMC Cancer       Date:  2008-01-31       Impact factor: 4.430

9.  Validation of tissue microarray technology in squamous cell carcinoma of the esophagus.

Authors:  Judith Boone; Richard van Hillegersberg; Paul J van Diest; G Johan A Offerhaus; Inne H M Borel Rinkes; Fiebo J W Ten Kate
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.